Phathom Pharmaceuticals, Inc.PHAT
Price (close)
$7.08
Market cap
$572.8M
P/E
—
Revenue (TTM)
$239.7M
Net income
-$99.1M
Dividend yield
—
1-year total return
-39.3%
Net margin
-41.3%
Revenue growth
110.2%
Debt / equity
—
What Phathom Pharmaceuticals, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $682,000 | $55.3M | $175.1M |
| Net income | -$129.1M | -$143.9M | -$197.7M | -$201.6M | -$334.3M | -$221.2M |
| Free cash flow | -$70.7M | -$148.8M | -$147.6M | -$139.2M | -$266.9M | -$167.0M |
More on PHAT.
- Phathom Pharmaceuticals, Inc. summary
- Phathom Pharmaceuticals, Inc. financial statements
- Phathom Pharmaceuticals, Inc. key metrics
- Phathom Pharmaceuticals, Inc. health scores and style box
- Phathom Pharmaceuticals, Inc. earnings
- Phathom Pharmaceuticals, Inc. dividends
- Phathom Pharmaceuticals, Inc. valuation
- Phathom Pharmaceuticals, Inc. ownership and insiders
- Phathom Pharmaceuticals, Inc. peers
Figures from Phathom Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.